ArticleCancer research communications2024

Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.

Torben Ek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.